BSGM

Merimepodib (MMPD)

COVID-19

Phase 2 (Data)

Exp Date

September 22, 2020

Amp Volatility Score

Catalyst Info & Data Links

MECHANISM OF ACTION / RATIONALE

  • Merimepodib is an inosine monophosphate dehydrogenase (IMPDH) inhibitor with activity against hepatitis C virus (HCV). IMPDH catalyzes the rate-limiting step in the de novo synthesis of guanine nucleotides, and treatment with merimepodib reduces the intracellular guanine nucleotide levels that are required for RNA and DNA synthesis, resulting in antiproliferative and antiviral effect (Learn more - National Library of Medicine). 

Updated by HC

#BSGM, #Merimepodib, #MMPD, #COVID

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Upcoming September 2020 COVID-...

Check out our AmpCards & #COVID19 catalyst tracker for investible small & mid-cap biopharma companies in the COVID therapeutics and vaccine race. Therapeutic candidate data from $VNDA, $BCRX, & $BSGM ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon